Lamotrigine blocks the initiation and expression of repeated high-dose methamphetamine-induced prepulse inhibition deficit in rats

Neuroscience Letters

Volumn 481, Issue 3, 2010, Pages 183-187

  Nakato, Yasuya ^a   Abekawa, Tomohiro ^a   Ito, Koki ^a   Inoue, Takeshi ^a   Koyama, Tsukasa ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Lamotrigine; Methamphetamine; Prepulse inhibition; Schizophrenia

Indexed keywords

LAMOTRIGINE; METHAMPHETAMINE; PSYCHOSTIMULANT AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG WITHDRAWAL; MALE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; STEADY STATE;

EID: 77955413906     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.07.002     Document Type: Article

References (39)

1. Abekawa T., Ito K., Nakagawa S., Nakato Y., Koyama T. Olanzapine and risperidone block a high dose of methamphetamine-induced schizophrenia-like behavioral abnormalities and accompanied apoptosis in the medial prefrontal cortex. Schizophr. Res. 2008, 101:84-94.
2. Adler C.M., Malhotra A.K., Elman I., Goldberg T., Egan M., Pickar D., Breier A. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am. J. Psychiatry 1999, 156:1646-1649.
3. Bakshi V.P., Geyer M.A. Multiple limbic regions mediate the disruption of prepulse inhibition produced in rats by the noncompetitive NMDA antagonist dizocilpine. J. Neurosci. 1998, 18:8394-8401.
4. Bakshi V.P., Swerdlow N.R., Geyer M.A. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J. Pharmacol. Exp. Ther. 1994, 271:787-794.
5. Baucum A.J., Rau K.S., Riddle E.L., Hanson G.R., Fleckenstein A.E. Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanism. J. Neurosci. 2004, 24:3436-3443.
6. Braff D.L., Swerdlow N.R., Geyer M.A. Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. Am. J. Psychiatry 1999, 156:596-602.
7. Brody S.A., Geyer M.A., Large C.H. Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice. Psychopharmacology (Berl.) 2003, 169:240-246.
8. Cunningham M.O., Jones R.S. The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology 2000, 39:2139-2146.
9. Farber N.B The NMDA receptor hypofunction model of psychosis. Ann. N. Y. Acad. Sci. 2003, 1003:119-130.
10. Geddes J.R., Calabrese J.R., Goodwin G.M. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br. J. Psychiatry 2009, 194:4-9.
11. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl.) 2001, 156:117-154.
12. Hoffman H.S., Searle J.L. Acoustic and temporal factors in the evocation of startle. J. Acoust. Soc. Am. 1968, 43:269-282.
13. Idris N.F., Repeto P., Neill J.C., Large C.H. Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and d-amphetamine in the rat. Psychopharmacology (Berl.) 2005, 179:336-348.
14. Ito K., Abekawa T., Koyama T. Relationship between development of cross-sensitization to MK-801 and delayed increases in glutamate levels in the nucleus accumbens induced by a high dose of methamphetamine. Psychopharmacology (Berl.) 2006, 187:293-302.
15. Ito K., Abekawa T., Koyama T. Valproate blocks high-dose methamphetamine-induced behavioral cross-sensitization to locomotion-inducing effect of dizocilpine (MK-801), but not methamphetamine. Psychopharmacology (Berl.) 2006, 186:525-533.
16. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991, 148:1301-1308.
17. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45:789-796.
18. Kane J.M., Marder S.R., Schooler N.R., Wirshing W.C., Umbricht D., Baker R.W., Wirshing D.A., Safferman A., Ganguli R., McMeniman M., Borenstein M. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch. Gen. Psychiatry 2001, 58:965-972.
19. Karceski S., Morrell M.J., Carpenter D. Treatment of epilepsy in adults: expert opinion. Epilepsy Behav. 2005, 7(Suppl. 1):S1-S64.
20. Krystal J.H., D'Souza D.C., Karper L.P., Bennett A., Abi-Dargham A., Abi-Saab D., Cassello K., Bowers M.B., Vegso S., Heninger G.R., Charney D.S. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology (Berl.) 1999, 145:193-204.
21. Krystal J.H., D'Souza D.C., Mathalon D., Perry E., Belger A., Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl.) 2003, 169:215-233.
22. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51:199-214.
23. Kumari V., Sharma T. Effects of typical and atypical antipsychotics on prepulse inhibition in schizophrenia: a critical evaluation of current evidence and directions for future research. Psychopharmacology (Berl.) 2002, 162:97-101.
24. Lees G., Leach M.J. Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neurological cultures from rat cortex. Brain Res. 1993, 612:190-199.
25. Lieberman J.A., Koreen A.R., Chakos M., Sheitman B., Woerner M., Alvir J.M., Bilder R. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J. Clin. Psychiatry 1996, 57(Suppl. 9):5-9.
26. Lieberman J.A., Sheitman B., Chakos M., Robinson D., Schooler N., Keith S. The development of treatment resistance in patients with schizophrenia: a clinical and pathophysiologic perspective. J. Clin. Psychopharmacol. 1998, 18:20S-24S.
27. Lingamaneni R., Hemmings H.C. Effects of anticonvulsants on veratridine- and KCl-evoked glutamate release from rat cortical synaptosomes. Neurosci. Lett. 1999, 276:127-130.
28. Pukrop R., Schultze-Lutter F., Ruhrmann S., Brockhaus-Dumke A., Tendolkar I., Bechdolf A., Matuschek E., Klosterkotter J. Neurocognitive functioning in subjects at risk for a first episode of psychosis compared with first- and multiple-episode schizophrenia. J. Clin. Exp. Neuropsychol. 2006, 28:1388-1407.
29. Sandoval V., Riddle E.L., Ugarte Y.V., Hanson G.R., Fleckenstein A.E. Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. J. Neurosci. 2001, 21:1413-1419.
30. Schwabe K., Koch M. Role of the medial prefrontal cortex in N-methyl-d-aspartate receptor antagonist induced sensorimotor gating deficit in rats. Neurosci. Lett. 2004, 355:5-8.
31. Sheitman B.B., Lieberman J.A. The natural history and pathophysiology of treatment resistant schizophrenia. J. Psychiatr. Res. 1998, 32:143-150.
32. Sills T.L. Amphetamine dose dependently disrupts prepulse inhibition of the acoustic startle response in rats within a narrow time window. Brain Res. Bull. 1999, 48:445-448.
33. Simoes P.F., Silva A.P., Pereira F.C., Marques E., Grade S., Milhazes N., Borges F., Ribeiro C.F., Macedo T.R. Methamphetamine induces alterations on hippocampal NMDA and AMPA receptor subunit levels and impairs spatial working memory. Neuroscience 2007, 150:433-441.
34. Snyder S.H. Amphetamine psychosis: a " model" schizophrenia mediated by catecholamines. Am. J. Psychiatry 1973, 130:61-67.
35. Stirling J., White C., Lewis S., Hopkins R., Tantam D., Huddy A., Montague L. Neurocognitive function and outcome in first-episode schizophrenia: a 10-year follow-up of an epidemiological cohort. Schizophr. Res. 2003, 65:75-86.
36. Swerdlow N.R., Geyer M.A., Braff D.L. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl.) 2001, 156:194-215.
37. Swerdlow N.R., Light G.A., Cadenhead K.S., Sprock J., Hsieh M.H., Braff D.L. Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function. Arch. Gen. Psychiatry 2006, 63:1325-1335.
38. Tiihonen J., Wahlbeck K., Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr. Res. 2009, 109:10-14.
39. + channel expressed in a stable mammalian cell line. Pflugers Arch. 2001, 441:425-433.